MCL1 and neuroblastoma: In neuroblastomas, a coupled siRNA screen identified that knockdown of splice factors UBL5 (ubiquitin-like protein 5), PRPF8 (pre-mRNA-processing-splicing factor 8), and SART (squamous cell carcinoma antigen recognized by T-cells) could restore sensitivity to ABT-737 in MCL1-dependent neuroblastomas and increased MCL1 splicing to produce more MCL1S variant [51].